The convergence of earnings calls on a specific Thursday isn't arbitrary. A former CFO explains it stems from the lengthy internal process of closing books, auditor reviews, and board coordination, forcing companies to report as late as possible within the required window.
A former CFO reveals that the extensive internal preparation for quarterly earnings calls—often over 100 hours—provides little value for smaller biotechs with minimal updates. He advises them to redirect those resources toward more impactful activities.
Private biotech CEO Jake Beecroft argues that large pharma mergers harm innovation. They create R&D uncertainty lasting over 18 months, freeze capital that would otherwise go to partnerships, and ultimately remove a key potential acquirer or partner from the ecosystem.
Reverse mergers are no longer a 'back door' listing method. Their acceptance by high-quality companies is driven by the concurrent PIPE financing, which recapitalizes the company and brings in a supportive, institutional shareholder base, mitigating the risk of inheriting a mismatched investor group.
The path to a successful biotech IPO has changed. The traditional VC-to-public handoff is obsolete. Now, securing pre-IPO investment from public market funds in a 'crossover' round is critical to ensure the offering is oversubscribed and well-received from the start.
The current IPO window is healthier than the 2020-21 peak because it's dominated by clinical-stage companies. Public markets are historically poor at durably valuing preclinical assets, so a surge of preclinical IPOs would be a negative signal of a 'FOMO-driven' market.
The challenge from China in biotech isn't just about their progress; it's a mirror reflecting America's self-inflicted inefficiencies. The U.S. has become too slow for early-stage trials, lagging even Australia, which has one-tenth the population but runs four times as many first-in-human studies.
The FDA's request for a new Phase 3 trial from Miram, despite strong pivotal data, highlights a growing unpredictability. This decision contradicts the recent approval of a competitor's drug with weaker data, signaling a puzzling and conservative shift that experts didn't anticipate.
The standard of care for melanoma is improving so quickly that control arms in recent clinical trials are significantly outperforming historical data. This 'rising tide' effect makes it increasingly difficult for new drugs to show a statistically significant benefit, creating high unpredictability for developers.
Otsuka's 24-month data for its IgA nephropathy (IGAN) drug shows it essentially stops disease progression, with some patients even improving their kidney function from baseline. Experts suggest this is a paradigm shift from treatment to what looks like a functional cure for a leading cause of kidney failure.